- Cerebras Crashes AI Party With Breakout IPO
May 14, 2026
Cerebras Crashes AI Party With Breakout IPO - Moby
BREAKING NEWS
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Cerebras Systems opened at $350 on its Nasdaq debut Thursday after pricing at $185, raising $5.55 billion in the largest US tech IPO since Uber went public in 2019 (but without all the Kalanick of it all). The company originally planned to sell shares at $115 to $125. Wall Street had other ideas. If underwriters exercise their option on an additional 4.5 million shares, total proceeds hit $6.38 billion and the valuation clears $100 billion, which is a lot of money for a company most people hadn't heard of 48 hours ago.
The business is real, which helps. Cerebras did more than $510 million in revenue in fiscal 2025, holds a multi-year compute deal with OpenAI valued at over $20 billion, and has a cloud deployment partnership with AWS. The valuation has more than doubled since February. At some point the AI enthusiasm and the underlying fundamentals have to reconcile, but Thursday was not that day.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
The architecture story is genuinely interesting. Nvidia slices its silicon wafers into small individual chips and connects them together, which works extraordinarily well until the data traffic between those chips becomes the problem. Cerebras keeps the entire dinner-plate-sized wafer intact as one continuous circuit, cutting the distance data travels from centimeters to millimeters and removing the bottleneck that slows AI training and inference. Nvidia built a very fast highway. Cerebras argues you don't need the highway if you remove the distance.
Nvidia is aware of the argument. Its next-generation Vera Rubin platform is a pre-built supercomputer engine designed to answer exactly this challenge. The AI compute war just got a new publicly traded combatant, and it arrived with a $100 billion valuation and a lot to prove.
View Comments
- Cerebras IPO: Here's What a $5,000 Investment Could Look Like in 5 Years
May 13, 2026
Key Points
Cerebras is an artificial intelligence (AI) chip designer that competes with Nvidia. The company is seeking to raise $4.8 billion in its IPO. While investing in IPOs seems exciting, history offers some telling clues as to whether following early momentum is worth it. 10 stocks we like better than Palantir Technologies ›
The artificial intelligence (AI) infrastructure race has produced no shortage of headline-grabbing companies. With its initial public offering (IPO) set for May 14, Cerebras may be the most closely followed infrastructure name at the moment. The chipmaker is known for its Wafer-Scale Engine (WSE) -- a single chip designed to handle the computational demands of large language models (LLMs) more efficiently than clusters of traditional GPUs.
This capability has caught the attention of leading AI powerhouses OpenAI and Amazon Web Services (AWS). Back in January, OpenAI signed a multiyear, $10 billion deal with Cerebras to purchase 750 megawatts of compute capacity. More recently, the ChatGPT developer doubled down on this relationship by agreeing to purchase $20 billion worth of the company's chips. Meanwhile, AWS agreed to deploy Cerebras' CS-3 system and Elastic Fabric Adapter (EFA) networking on Amazon Bedrock.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
With these wins so close to its public debut, Cerebras' IPO price range has increased to $150 to $160 per share -- meaningfully higher than its initial band of $115 to $125. At the high end of this range, Cerebras would be valued at roughly $49 billion, more than double its valuation in its most recent funding round in February.
Smart investors are wondering whether this premium will hold in the coming years. Let's take a look at some recent high-profile technology IPOs to determine whether you should invest in the Cerebras IPO this week.
Image source: Getty Images.
How do IPOs actually work?
When a company goes public, the IPO price is set through a process called book building, during which underwriters (investment banks) gauge institutional demand and price shares accordingly. Retail investors rarely have access to IPO shares at this stage. By the time an IPO stock begins trading on the open market, momentum investors, hedge funds, and media coverage have typically pushed the stock above its offering price.
While these pops can feel like validation, they are usually a mirage of manufactured excitement rather than a genuine assessment of a company's intrinsic value. Moreover, the stock float at the IPO date is usually pretty small. This means only a modest amount of buying activity can send shares soaring.
IPO case studies: Palantir and Snowflake
Palantir Technologies(NASDAQ: PLTR) and Snowflake(NYSE: SNOW) both went public in 2020.
Palantir debuted through a direct listing, with shares opening near $10. Wall Street initially treated Palantir with skepticism. In the eyes of most analysts, Palantir was a government contractor with a slow-growing commercial segment and persistent operating losses.
After launching its Artificial Intelligence Platform (AIP) in early 2023, Palantir was able to reinvent itself as an operating system for large corporate enterprises and government agencies. This pivot proved transformational, as shares have now climbed roughly 1,270% from their IPO price over the last five years or so.
Meanwhile, Snowflake tells the complete opposite story. Priced at $120 per share, shares closed at $254 on their first day of trading. By late 2021, Snowflake stock had peaked near $402.
Rising interest rates in 2022 negatively impacted growth stocks trading at premium valuations. Snowflake, which had been trading at a price-to-sales (P/S) multiple of over 200, was hit hard. While the business continued growing, the company's valuation profile was totally reset.
Today, Snowflake stock trades around $154 -- meaning investors who bought shares near its first-day close are still sitting on a loss nearly five years later.
Where could Cerebras be trading in five years?
The tension at the heart of high-profile IPOs is that the story is often real, but the premium embedded in the opening day price already reflects outsize levels of optimism. Investors who follow momentum-driven pops are paying not for where the business truly is today, but for what the market imagines it could become under bullish conditions. And investors often forget that lock-ups expire, triggering waves of selling from insiders and employees.
Cerebras enters the public markets carrying specific risks that smart investors are paying close attention to. Among the most glaring is customer concentration. Almost 90% of Cerebras' revenue stems from two customers. If the relationships with OpenAI or AWS deteriorate for any reason, the company's revenue trajectory essentially goes back to where it is today.
The current valuation profile also prices Cerebras to perfection. At about 95x 2025 sales, there is no margin for error. Meanwhile, the competitive landscape is packed. Nvidia's and AMD's entrenched positions in GPUs and AI accelerators, combined with custom silicon efforts from Broadcom, mean Cerebras will need to justify why its architectural advantage is durable.
A $5,000 investment in the Cerebras IPO could look like Palantir -- a rough early stretch followed by a multibagger return if the company makes AI infrastructure indispensable to the hyperscalers. However, it could just as easily look like Snowflake -- a jaw-dropping opening followed by years of valuation de-rating as the business grows but never quite matches what investors initially paid.
Investing in the Cerebras IPO at its current price assumes paying a premium, arguably before it should exist. That could be a bet worth taking, but only for investors who can tolerate volatility and uncertainty.
Should you buy stock in Palantir Technologies right now?
Before you buy stock in Palantir Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $472,744!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,353,500!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 13, 2026.
Adam Spatacco has positions in Amazon, Nvidia, and Palantir Technologies. The Motley Fool has positions in and recommends Advanced Micro Devices, Amazon, Broadcom, Nvidia, Palantir Technologies, and Snowflake. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Morning Minute: Wall Street Loads Up on Bitcoin
Aug 18, 2025
Morning Minute is a daily newsletter written by Tyler Warner. The analysis and opinions expressed are his own and do not necessarily reflect those of Decrypt. Subscribe to the Morning Minute on Substack.
GM!
Today's top news:
Crypto majors dip 3-6% overnight; BTC holds at $115,000 Gemini files to go public with ticker GEMI, timing TBD BTCS becomes first TreasuryCo to issue a ‘Bividend’, offers blockchain dividend Adam Back’s Bitcoin Standard TreasuryCo to launch with 30k BTC + $1.5B LIGHT eco rallies over the weekend, latest launchpad challenger to Pump
🏦 Wall Street Loads Up on Bitcoin via ETFs
Some of the biggest players in the world are piling billions into BTC funds.
Yet the average professional fund manager is barely allocated. What gives?
📌 What Happened
Wall Street and global institutions dramatically increased their Bitcoin exposure in Q2, pouring billions into spot ETFs like BlackRock’s (IBIT) and related crypto equities.
SEC filings reveal that heavyweights like Brevan Howard, Goldman Sachs, Harvard, Wells Fargo, Jane Street, and even Norway’s sovereign wealth fund all boosted their positions, signaling growing comfort with BTC as a core allocation.
Some of the most notable moves:
Brevan Howard nearly doubled its IBIT stake to 37.9M shares worth $2.6B, making it one of the largest institutional holders. Goldman Sachs reported $3.3B across IBIT and Fidelity’s Wise Origin Bitcoin Trust (FBTC), plus $489M in Ethereum’s ETHA trust. Harvard disclosed a $1.9B stake in IBIT, while Abu Dhabi’s Mubadala continues to hold $681M. Wells Fargo quadrupled IBIT holdings to $160M, alongside a small GBTC stake. Cantor Fitzgerald pushed past $250M in IBIT while adding exposure to Strategy (MSTR), Coinbase (COIN), and Robinhood (HOOD). Trading giant Jane Street now owns $1.46B of IBIT, making it its largest position after Tesla. Norway’s $2T sovereign wealth fund indirectly holds 7,161 BTC (~$841M) via equity stakes in MSTR, Coinbase, Block, and others - up 192% YoY.
Yet, the average professional fund manager in the US is barely allocated.
A survey from Bank of America showed that the average fund manager has just 0.3% allocated to crypto.
And a whopping 75% have 0 exposure.
🗣️ Why It Matters
It’s a tale of two groups.
Story Continues
Institutions are clearly piling into BTC and crypto right now, including the biggest names in finance, academia, and even nation-states.
The sheer scale of these positions ($2B+ for Brevan Howard, $3B+ for Goldman, $1.9B for Harvard) validates Bitcoin as an institutional-grade asset.
And it’s becoming clearer that spot ETFs are proving to be the gateway, offering clean, regulated exposure through familiar structures.
Yet, retail is sleeping, and their fund managers aren’t helping.
The fact that 75% of fund managers aren’t allocated at all is not surprising but is also staggering at the same time.
But the good news is - they are coming.
The more that the big names and institutions pile in, the “safer” it becomes for the average fund manager to recommend crypto as an investment.
It’s a lot easier to make safe, standard and consensus plays and collect fees than it is to go out on a limb and make contrarian, conviction calls.
Crypto won’t be contrarian much longer.
And the fund manager pivot is just a matter of time…
🌎 Macro Crypto and Memes
A few Crypto and Web3 headlines that caught my eye:
Crypto majors were red on the day; BTC -3% at $115,100, ETH -6% at $4,260, XRP -5% at $2.97, SOL -7% at $181 XMR (+4%) led top movers Odds of a September rate cut have fallen from 99% to 83% after recent inflation data The ETH ETFs saw new outflows on Friday, after a massive 8-session green streak that resulted in $3.7B in net inflows The Federal Reserve officially ended its “novel activities” program that increased bank scrutiny of crypto SEC Chair Paul Atkins announced the agency is developing new custody regulations for digital assets to increase clarity and security in the U.S. crypto markets A recent survey showed professional fund managers allocate just 0.3% to crypto on average, and 75% have 0 exposure Gemini filed to go public via Nasdaq with ticker GEMI, timing still TBD Grayscale filed for a Dogecoin ETF on Friday New York Assemblymember Phil Steck proposed a 0.2% excise tax on crypto transactions, estimating $158 M in annual revenue from the program
In Corporate Treasuries
SBET stock plunged 15% to $19.85 on Friday following a Q2 net loss of $103 M; the firm attributed losses to a $87.8M non‑cash impairment and $16.4M in stock‑based compensation Metaplanet bought another 775 BTC for $93M, now holds 18,888 Adam Back’s Bitcoin Standard TreasuryCo is preparing to go public in a merger with Cantor Equity Partners, aiming to launch with 30,000 BTC + $1.5B in capital BTCS announced it will issue a one-time blockchain dividend, 'Bividend,' of $0.05 per share in ETH, the first of its kind
In Memes
Memecoin leaders are very red on the day; DOGE -5%, Shiba -5%, PEPE -5%, PENGU -6%, BONK -8%, TRUMP -2%, SPX -9%, and FARTCOIN -5% FORK was a top onchain runner, jumping 25x to $4.3M; NEET +36% to $13M was a notable mover LIGHT ran 4x to $160M over the weekend after the team spent over $1.4M buying back and burning its token thanks to its flywheel (now $126M)
💰 Token, Airdrop & Protocol Tracker
Here's a rundown of major token, protocol and airdrop news from the day:
Polymarket introduced a 'Breaking News' tab, showing the top moving markets over the past 24 hours Pump.fun flipped Hyperliquid in revenue on Sunday, though it still lagged on the week and month (Hype re-flipped it over the past 24 hours) Story Protocol founder Jason Zhao resigned over the weekend, 3.5 years after starting Story (and $130M+ in funding later)
🤖 AI x Crypto
Section dedicated to headlines in the AI sector of crypto:
Overall market cap down 3% to $12.9B, leaders were red FARTCOIN (-6%), VIRTUAL (-3%), TIBBIR (-8%), ai16z (-5%) & VVV (+9%) VIRGEN (+84%), AVB (+17%) and CLANKER (+15%) led top movers
🚚 What is happening in NFTs?
Here is the list of other notable headlines from the day in NFTs:
ETH NFT leaders were red alongside the ETH selloff; Punks -1% at 49 ETH, Pudgy -3% at 12.8, BAYC -3% at 11.3 ETH 0n1 Force (+29%) and Yumemono (+60%) were notable top movers Bitcoin NFTs saw some green, led by Taproot Wizards (+4%) and Adderrels (+28%) Abstract NFTs were mostly red, led by Pengztracted (+29%) A Rektguy 1/1 sold for 10 ETH ($45,000) Cerebro announced its mint details, launching on 8/21 with 6,969 NFTs for 0.08 ETH each
View Comments
- CERE DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
Jun 3, 2025 · accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / WHY: New York, N.Y., June 3, 2025.
- CERE DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, ENCOURAGES CEREVEL THERAPEUTICS HOLDINGS, INC. INVESTORS TO SECURE COUNSEL BEFORE IMPORTANT JUNE 3 DEADLINE IN SECURITIES CLASS ACTION - CERE
Jun 3, 2025
NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 3, 2025 / WHY: NEW YORK, N.Y., JUNE 3, 2025.
- CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Jun 3, 2025 · businesswire.com
NEW YORK--(BUSINESS WIRE)---- $CERE #CERE--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”) and reminds investors of the June 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities l.
- CERE INVESTORS HAVE THE OPPORTUNITY TO LEAD THE CEREVEL SECURITIES FRAUD LAWSUIT WITH FARUQI & FARUQI, LLP
Jun 3, 2025
NEW YORK--(BUSINESS WIRE)---- $CERE #CERE--FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST CEREVEL THERAPEUTICS HOLDINGS, INC. (“CEREVEL” OR THE “COMPANY”) (NASDAQ: CERE), BAIN CAPITAL INVESTORS, LLC (“BAIN”) AND PFIZER, INC. (“PFIZER”) AND REMINDS INVESTORS OF THE JUNE 3, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. FARUQI & FARUQI IS A LEADING NATIONAL SECURITIES L.
- FINAL REMINDER CERE DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Cerevel Therapeutics Holdings, Inc. Investors to Participate in the Class Action Lawsuit
Jun 3, 2025 · accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
- FINAL REMINDER CERE DEADLINE: BRONSTEIN, GEWIRTZ & GROSSMAN LLC ALERTS CEREVEL THERAPEUTICS HOLDINGS, INC. INVESTORS TO PARTICIPATE IN THE CLASS ACTION LAWSUIT
Jun 3, 2025
NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 3, 2025 / BRONSTEIN, GEWIRTZ & GROSSMAN, LLC, A NATIONALLY RECOGNIZED LAW FIRM, NOTIFIES INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST CEREVEL THERAPEUTICS HOLDINGS, INC. ("CEREVEL" OR "THE COMPANY") (NASDAQ:CERE), BAIN CAPITAL INVESTORS, LLC ("BAIN") AND PFIZER, INC. ("PFIZER"). CLASS DEFINITION THIS LAWSUIT SEEKS TO RECOVER DAMAGES AGAINST DEFENDANTS FOR ALLEGED VIOLATIONS OF THE FEDERAL SECURITIES LAWS ON BEHALF OF ALL PERSONS AND ENTITIES THAT: (A) SOLD OR OTHERWISE DISPOSED OF THE PUBLICLY-TRADED COMMON STOCK OF CEREVEL DURING THE PERIOD FROM OCTOBER 11, 2023 THROUGH AUGUST 1, 2024, INCLUSIVE, AND THUS WERE DAMAGED BY DEFENDANTS' VIOLATIONS OF SECTION 10(B) OF THE SECURITIES EXCHANGE ACT OF 1934 ("EXCHANGE ACT"); (B) HELD SHARES OF CEREVEL AS OF JANUARY 8, 2024 (THE "RECORD DATE") AND WERE ENTITLED TO VOTE ON THE MERGER OF CEREVEL AND ABBVIE INC. ("ABBVIE") AND THUS WERE DAMAGED BY DEFENDANTS' VIOLATIONS OF SECTION 14(A) OF THE EXCHANGE ACT; AND/OR (C) SOLD SHARES OF CEREVEL STOCK CONTEMPORANEOUSLY WITH BAIN'S PURCHASE OF SHARES ON OR ABOUT OCTOBER 16, 2023 AND THUS WERE DAMAGED BY BAIN'S VIOLATIONS OF SECTION 20A OF THE EXCHANGE ACT.
- CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Jun 2, 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQ: CERE), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”).
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024 inclusive, and thus were damaged by defendants’ violations of Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”); (b) held shares of Cerevel as of January 8, 2024, (the “Record Date”) and were entitled to vote on the merger of Cerevel and AbbVie Inc. (“AbbVie”) and thus were damaged by defendants’ violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain’s purchase of shares on or about October 16, 2023 and thus were damaged by Bain’s violations of Section 20A of the Exchange Act. Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/CERE.
Case Details
The Complaint alleges that Cerevel’s Offering documents and other public statements omitted material facts regarding AbbVie’s interest in acquiring Cerevel at a price well in excess of the $22.81 per share Offering price, artificially deflating Cerevel’s stock price until the merger was announced. Moreover, Specifically, the Complaint alleges that: (1) Cerevel’s controlling shareholder, Bain, acquired Cerevel shares from the October Offering at an artificially depressed price while allegedly in possession of material nonpublic information regarding AbbVie’s interest; (2) On December 6, 2023 (less than two months after the October Offering), Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share and that the merger allowed Bain to receive a windfall of more than $120 million on the shares it acquired at the artificially depressed Offering price.
The Action also seeks to recover damages on behalf of investors that held shares as of the January 8, 2024 Record Date and were damaged as a result of Defendants’ allegedly false and misleading statements and omissions of material facts in Cerevel’s January 18, 2024 Proxy statement (the “Proxy”). Among other things, the Complaint alleges the Proxy misled investors regarding the true nature and timing of AbbVie’s interest in Cerevel.
What's Next?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/CERE, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Cerevel you have until June 3, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
